December 5, 2007
Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotechnology industries, today announced that Ben Bonifant, Vice President of the firm’s Business Development practice, will serve as conference chairperson and deliver the keynote presentation at the Strategic Research Institute’s (SRI) Pharma & Biotech Licensing and Deal-Making Summit. The event will be held on
Mr. Bonifant’s keynote address, titled “When to Do the Deal: How to Know the Time Is Right,” will be the opening presentation on Monday, December 10, at The session will address the difficulty licensing executives face when trying to identify the point when risk and financial reward are optimally balanced. Making this decision is difficult because the characteristics and risk profiles of each asset vary. In addition, Mr. Bonifant will dissect other common problems facing licensing executives and outline an approach that decision-makers can apply to answer the question, “When should we do the deal?”
“For licensing executives, the question of when to complete a deal can be a difficult one. For example, an out-licensor may wonder if it makes more sense to complete a deal earlier in development, thereby transferring more risk to its partner but reducing its own financial rewards,” stated Mr. Bonifant. “On the other hand, the out-licensor may wonder if it’s better to wait until a later stage of development, exposing itself to greater risk of failure, but keeping the door open for greater financial returns,” Bonifant added.
Mr. Bonifant has been a management consultant for nearly 15 years, helping leaders of global pharmaceutical and biotech organizations and decision makers in large private equity funds. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals, and he is a frequent guest lecturer at some of the nation’s premier universities. Mr. Bonifant earned an MBA from the Stanford Graduate School of Business.
For more information on the
Executives from Campbell Alliance speak at many conferences in the
About the Business Development Practice at
The firm's team includes seasoned consultants and industry professionals in pharmaceutical and biotech BD who have identified, assessed, and executed numerous in-licensing deals. They have also been valuable in aiding out-licensors, helping clients improve internal processes for pharmaceutical business development, and assisting top executives in charting new strategies in corporate development.